Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

Phase 2CompletedNCT00202579

Institut de Recherches Internationales Servier12 enrolled

Overview

To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * systolic congestive heart failure * sinus rhythm, HR \>= 80bpm Exclusion Criteria: * unstable cardiovascular condition

Policlinico San Matteo

Pavia, Italy

Haemodynamic parameters

Twelve-lead ECG

Systolic and diastolic blood pressure

Echocardiography

Neurohormones

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.